

State of the ACTG Network

Judith Currier, MD
Network Chair
June 18, 2019



In Memoriam



Charlie van der Horst, MD



Kevin Robertson, PhD

Welcome



Accrual June 2018-May 2019

- 2511 participants enrolled

Interventional Trials: 1501

Observational Trials: 1010

US: 802

International: 1709

Completed Accrual

- 5332 REPRIEVE → 7500 participants!! (~4500 at ACTG sites)
- Enrolled 30% women



Completed Accrual

- 5320 - Hepatitis C Cohort Study
- 5324 - InMIND
- 5343 - A Trial of the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid
- 5349 - Rifapentine-Containing Treatment Shortening Regimens for Pulmonary Tuberculosis
- 5366 - Effects of SERM and HDACi on HIV-1
- 5378 - Safety & Virologic Effect of HIV-1 Specific Broadly Neutralizing Human MAbs (VRC01LS&VRC07523LS)

Opened

- 5360 MinMon
- 5369 Gag conserved element therapeutic vaccine
- 5378 VRC01LS Single dose
- 5359 LA ART

PHOENIX 5300B is OPEN



Congratulations to the Co:Chairs
Gavin Churchyard
Amita Gupta
Sue Swindells
Anneke Hesseling

CTS: Lara Hosey and Linda Naini

And to all the team members and sites

Opened (9 Studies)

- 5360 MinMon
- 5369 Gag conserved element therapeutic vaccine
- 5378 VRC01LS Single dose
- 5359 LA ART
- 5300B Phoenix
- 5377 First in Human Tri-specific Antibody
- 5370 Anti-PD1(Cemiplimab)
- 5375 Optimize Levonorgestrel with EFV or RIF
- 5381 TLD Rollout Observational Study*

In Development (n=18)

- 5355 CMV Vaccine
- 5356 Linezolid Dosing for DR-TB
- 5362 Clofazimine for DS TB
- 5357 VRC01 + LA CAB
- 5363 CVC for CVD
- 5368 Anti PD1 Ab for Hep B
- 5372 DDI DTG/Rifapentine
- 5373 INH Mono-resistant TB
- 5376 Etonorgestrel Implant DDI
- 5379 B-HIVE HBV vaccine
- 5380 PURGE-C (Acute Hep C)
- 5382 REP 2139-Mg Hep B cure
- 5371 NAFLD Treatment
- 5383 Letemovir and CMV (ELICIT)
- 5384 TB meningitis Rx
- 5385 Post treatment controller F/U
- 5386 IL-15 superagonist +/- BNabs
- 5387 2BNabs in acute infection

Proposals: PR, DACs, NWCS and DR

- 32 new Concept Proposals Submitted
 - 7 approved, 2 withdrawn
- Approved
 - 2 DACS
 - 18 DR
 - 17 NWCS

Currently under Review

- 8 Proposals
- 4 NWCS
- 3 DACS
- 1 DR

Abstracts and Publications

- June 2018-2019
 - 83 Abstracts presented at meetings, including 32 at CROI 2019
 - **80 Manuscripts published**
 - CID (18)
 - JAIDS (11)
 - AIDS (9)
 - JID (6)
 - OFID (6)
 - NEJM (2)
 - Plos One (2)
 - Science (1)

(J Clin Invest, J Virol, J Antimicrob Chem, J Wom Health, Anti Micro Chem, Sex Trans Dis, AIDS Res Hum Retro, others)

300 manuscripts have been published since the start of the current grant cycle in December 2013

New Initiatives

- Election of Regional International Representatives to foster development and input of investigators from International Sites
 - African Region: Johnstone Kumwenda
 - South American and Caribbean: Beatriz Grinsztejn
 - Asia: Nagalingeswaran Kumarasamy (Kumar)
- Expansion of the Mentored Research Training awards to include one international investigator.
- Addition of an annual Community Retreat (planned for November of 2019)
- Cross Network Scientific Working Group on TB vaccines with HVTN and IMPAACT

The next 4 days...

- Dr Fauci will present an update from NIH on Thursday
- Dr Kim will lead a session on important new regulations for our research programs Friday
- Plenary sessions to showcase data from completed trials
- Awards to recognize important contributions to the group
- Think Tanks, Business Sessions and Symposia to generate discussion and seek and engagement on the scientific agenda
- New Investigator Workshop- an introduction to working in the ACTG
- Trainings for several new studies
- Support committee meetings- discover what these important groups do
- Get involved, pack a lunch and enjoy- we need you!!

ACTG Leadership



Judith Currier
Network Chair



Joe Eron
Vice-Chair, Co-PI



Ian Sanne
International VC




Grace Aldrovandi
Lab Center PI



Sue Koletar
Chair, PEC



Michael Hughes
PI SDAC




Marlene Cooper
Director, DMC



Alexis Sexton
Director LOC



Dan Kuritzkes
Past Chair



Tina Brenneman
Director NCC